Globus Medical (GMED) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Total Cash From Operating Activities Chart for Globus Medical
Globus Medical (GMED) operating cash flow for FY2025 was USD 753.4M, a 44.7% change from FY2024. Globus Medical's operating cash flow grew from USD 32.1M in 2009 to USD 753.4M in 2025 (2248.7% over 16 years). Operating cash flow compound annual growth rate: 5-year CAGR of 30.5%, 10-year CAGR of 20.0%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $10.26B
- Implied Share Price
- $91.76
- Enterprise Value
- $9.45B
- Revenue (TTM)
- $3.14B
- EBITDA
- $1.01B
- Profit Margin
- 17.03%
- Trailing P/E
- 19.60
- Forward P/E
- 13.87
- Price/Book (MRQ)
- 2.08
- Price/Sales (TTM)
- 3.26
- EV/EBITDA
- 9.90
- EV/Revenue
- 3.00
- Dividend Yield
- —
- Book Value
- $35.52
- Free Cash Flow (FY2025)
- $588.77M
- Free Cash Flow Yield
- 5.74%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.